Actively Recruiting

Age: 18Years +
All Genders
NCT06365359

Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique

Led by University Hospital Center of Martinique · Updated on 2025-03-31

200

Participants Needed

1

Research Sites

86 weeks

Total Duration

On this page

Sponsors

U

University Hospital Center of Martinique

Lead Sponsor

I

Institut Pasteur de Guadeloupe

Collaborating Sponsor

AI-Summary

What this Trial Is About

Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population of the French West Indies by chlordecone. Epidemiological studies conducted in the French West Indies have shown that exposure to chlordecone at the levels observed is associated with an increased risk of developing several diseases, including premature birth and prostate cancer. Many of the adverse effects associated with chlordecone could be explained by its estrogenic hormonal properties, and systemic lupus erythematosus (SLE) is an autoimmune disease whose sensitivity to estrogen is well known and is reflected by 1) its clear predominance in women, 2) its predominance in women of childbearing age, 3) its risk of exacerbation in the event of pregnancy. Chlordecone has the potential to modify the activity of SLE through mechanisms other than its pro-estrogenic effects. In rats, chlordecone was observed to induce alterations such as a reduction in lymphocyte count, thymic atrophy, and a decrease in splenic germinal centers and NK cells. In a mouse model of systemic lupus erythematosus (SLE), exposure to chlordecone results in increased production of immune complexes and anti-DNA antibodies, which are markers of disease activity and monitoring. Chlordecone also has a cellular effect that reduces the apoptosis of potentially auto-reactive lymphocytes and stimulates the production of GM-CSF, IL-2, TNF-alpha, and IFN-gamma. The latter is central to the pathophysiology of SLE. While experimental studies suggest a potential impact of chlordecone on SLE, no human studies have been conducted to date, and the chlordecone impregnation of lupus patients in Martinique remains unknown. The most serious and feared complication of SLE is kidney damage. Kidney damage from the disease and the necessary immunosuppressive treatments can lead to significant morbidity and mortality, including death and end-stage chronic renal failure. Therefore, it is important to manage the disease carefully. Suspected lupus nephritis is confirmed by a renal biopsy, which allows for formal diagnosis and categorization into several classes. Suspected cases are identified by a proteinuria to creatininuria ratio greater than 0.5 g/g (or 24-hour proteinuria greater than 0.5g). The objective of this project is to determine whether there is a positive association between lupus nephritis occurrence in patients followed by the internal medicine department of the Martinique University Hospital and organochlorine pesticide chlordecone impregnation.

CONDITIONS

Official Title

Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with systemic lupus erythematosus according to ACR 1997 or ACR/EULAR 2019 criteria
  • Active patients in the internal medicine department of Martinique University Hospital since 2005
  • Disease progression of at least 3 years
  • Living in Martinique or Guadeloupe for at least 1 year
  • Provided free, informed, and written consent
Not Eligible

You will not qualify if you...

  • Kidney disease status cannot be confirmed due to refusal, contraindication, or inability to undergo renal biopsy
  • Lack of social security coverage
  • Under current legal protection
  • Have not consented to use of their data
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital Center of Martinique

Fort-de-France, France, 97261

Actively Recruiting

Loading map...

Research Team

B

Benoît SUZON, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here